Supplementary Agreement on New Drug Methionine-Enkephalin Cooperation

In October, 2012 , Hubei Qianjiang Pharmaceutical Co ., Ltd (a Chinese listed company) and TNI Biotech, Inc. (an American company) signed Cooperation Agreement on New Drug Methionine Enkephalin in Qianjiang, Hubei Province , China.

In August 5, 2014, Hubei Qianjiang Pharmaceutical Co., Ltd (hereinafter referred to as " Qi a njiang Pharmaceutical " ) and TNI Biotec h , In c . (hereinafter referred to as " TNI Biotech " ) signed Supplementary Cooperation Agreement on New Drug Methionine Enkephalin in America. TNI Biotech has established a great deal of studies since signed the agreements, including basic studies such as pharmaceutical studies, pharma toxicology studies, clinical trials and n ew -de ve loped indications. Such trials work smoothly, and sev e ral results ha ve got the approval of the Food and Drug Administration.

According to th e reports of TNI Biotec h , TNI Biotech has established phase I and II clinical trials as used for pancreatic cancer, and joined FDA meeting in August, 20 1 3 . In the meeting, FDA approved TNI Biotech in followin g aspects: developing MENK as l yoph ili ze d power and with administration route by iv or subcutaneous approving phase I and II clinical resu lts ; holding m eet ing on End of Phase II and d etermi nation of Phase III in America after TNI Biotech complement pharmaceutical studies and pharma-toxicology studies on MENK; evaluating the basic studies and trials by TNI Biotech on MENK as used for treating liver cancer. FDA approved a phase IIB study but has required a PK and Dosing Trial be run in parallel with the Phase IIB Trials.

To date, Hubei Qianjiang Pharmaceutical Co., Ltd has established great of marketing research, and pre-trials on pharmaceutical and pharma-toxicology studies, which have obtained positive results. In order to accelerate clinical trials in both America and China and many other researches and developments, both parties agree:

Exploratory Toxicology (nGLP)

Definitive Toxicology (GLP)

Special toxicology studies (planned)

This amendment will be going to effect after signature by two parties

ASSIGNMENT

WHEREAS, Professor Fengping Shan Ph.D., of No.92 North Second Road, Department of Immunology, China Medical University, Shenyang, Liaoning China 110001 (hereinafter Assignor), is the owner of the entire right, title and interest in and to the following listed Patents and/or Patent Applications (hereinafter Patents) in China by previous assignments;

1)   化合物蛋氨酸 脑 啡 肽 作 为 制 备 治 疗 血液、骨髓造血系 统 癌 症 药 物的 应 用 CN 200710158742.7 Met-enkephalin, its application in in treating leukemia and

other blood cancers;

2)   蛋氨酸 脑 啡 肽 在制 备 人或 动 物接种疫苗中的 应 用 CN 200710051586.4 Met-enkephalin, its application in preparation of human and animal vaccine;

3)   种含有蛋氨酸 脑 啡 肽 的气 雾剂 CN 200610046249.1 A nasal spray formulation containing Met enkephalin;

4)   纳 曲 酮联 合蛋氨酸 脑 啡 肽 作 为 制 备 癌症 药 物中的 应 用 , CN 201210290150.1 Low dose naltrexone, combined with MENK, its application in preparation of anticancer drug;

5)   低 剂 量 纳 曲 酮联 合蛋氨酸 脑 啡 呔 作 为 制 备 抗癌 药 物的 应 用 CN 201210302259.2 Low dose naltrexone, combined with MENK, its application in preparation of leukophoresis for anticancer;

6)   化合物蛋氨酸 脑 啡 肽 作 为 制 备 治 疗肠 癌、胰腺癌 药 物的 应 用 CN 200810229085.5

Conpound met-enkephalin as a drug for colon cancer and pancreatic cancer using a method of by

isolating and enriching a patient's own immune cells and following an enriching external

incubation are transfused back into the patient thereby providing the patient with a passive

immunity containing large amounts of auto-amplified immune cells that combat cancer cells.;

WHEREAS, TNI BioTech, Inc. (hereinafter Assignee), a corporation organized and existing under and by virtue of the laws of United States of America, having an office at 618 East South Street #500, Orlando, FL 32801, is desirous of acquiring the entire right, title and interest in and to the inventions described and claimed in said;

NOW, THEREFORE, for good and valuable consideration, the receipt of and sufficiency of which are hereby acknowledged, said Assignor has sold, assigned and transferred and does hereby sell, assign and transfer unto said Assignee, its successors and assigns, its entire undivided right, title and interest in and to the said Patents and the inventions therein contained, including the right to sue for past infringement, to be held and enjoyed by said Assignee, its successors and assigns, the same as it would have been held and enjoyed by said Assignor if this assignment and sale had not been made.

Said Assignor hereby represents and warrants that there are no rights or interests outstanding inconsistent with the rights and interest granted herein and that said Assignor will not execute any instrument or grant or transfer any rights or interests inconsistent therewith, and said Assignor binds itself and its heirs, executors, administrators, employees and legal representatives, as the case may be, to execute and deliver to said Assignee, its successors and assigns, any further documents or instruments and do any and all further acts that may be deemed necessary by said Assignee, its successors and assigns, to file applications for improvements and inventions in any country where it may elect to file such applications, and that may be necessary to vest in said Assignee, its successors and assigns, the title herein conveyed, or intended so to be, and to enable such title to be recorded in the United States and foreign countries where such application or applications may be filed.

AND, said Assignor further covenants and agrees, in consideration of the premises, that it, its executors and administrators, will, at any time upon request, communicate to said Assignee, its successors and assigns, any facts relating to the said invention and improvements and the history thereof, known to it or its successors and assigns, and that it will testify as to the same in any interference or other proceeding when requested to do so by said Assignee, its successors and assigns.

The undersigned hereby grants the law firm of Birch, Stewart, Kolasch & Birch, LLP the power to insert on this Assignment any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

IN TESTIMONY WHEREOF, said Assignor has hereunto set its seal this 5th day of  August , 2014.

/s/Fengping Shan

Fengping Shan Ph.D. (signed August 6, 2014)